CD19 negative diffuse large B‐cell lymphoma presenting in leukemic phase

Issue highlights—July 2023

“…In a rare case study, Ramalingam et al reported a patient with CD19‐negative diffuse large B‐cell lymphoma (DLBCL). Since CD19 is currently the primary gating marker for B cell neoplasms, its absence may lead to erroneous results and potentially affect therapeutic strategies, so the authors (Ramalingam et al, 2022). Challenges for flow cytometry approaches have been studied before (Gao, Chen, et al, 2023; Gao, Liu, et al, 2023; Huang et al, 2023; Martig & Fromm, 2022).…”